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Chronic lymphocytic leukemia (CLL), defined by accumulation of pathogenic B cells, has a very complex
biology due to various factors such as inherited, host, and enviromental factors. Recently, finding new
therapeutic agents or development of novel treatment strategies have been paid attention. Resveratrol and
quercetin, important phytoalexins found in many plants, have been reported to have cytotoxic effects on
various types of cancer. In this study, we examined cytotoxic, cytostatic, and apoptotic effects of these
two important phenolic compounds on 232B4 human CLL cells. Cytotoxic effects of resveratrol and
quercetin were determined by MTT cell proliferation assay. Changes in caspase-3 enzyme activity were
measured using caspase-3 colorimetric assay. Annexin V-FITC/PI double staining was performed to
measure apoptotic cell population. Effects of resveratrol and quercetin on cell cycle profiles of CLL cells
were investigated by flow cytometry. Treatment of CLL cells with resveratrol and quercetin caused dose
dependent inhibition of cell proliferation and increased apoptotic cell population through induction of
caspase-3 activity. Cell cycle analysis displayed cell cycle arrest mainly in G0/G1 for both polyphenols.
Our data, in total, showed for the first time that resveratrol and quercetin might block CLL growth through
inducing apoptosis and cell cycle arrest.
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Introduction
Chronic lymphocytic leukemia (CLL), the most
common type of leukemia in the Western world,
affects mainly adults.1 CLL cells are originated from
antigen-stimulated mature B lymphocytes that either
avoid death by external signals or die by apoptosis.
Therefore, CLL is characterized by the clonal prolifer-
ation and accumulation of antigen experienced B lym-
phocytes in the blood, bone marrow, lymph nodes,
and spleen.2,3 Several genetic aberrations have been
identified in CLL. The most common one is a deletion
at 13q14.3 (IGHV). The other mutations include
11q22–23 (ATM), 17p13 (p53), and 6q21 deletions.4
These abnormalities are responsible for the formation
of CLL and some of its clinical outcomes.
Although there are many therapeutic regimens,
CLL is still an incurable disease.1 Current treatment
possibilities include conventional chemotherapy,
monoclonal antibodies and hematopoietic transplan-
tation.5 However, these standart treatment methods
are not sufficient to remove all CLL cells and have
their own side effects. Therefore, developing new strat-
egies or agents that could eliminate CLL cells, resistant
to apoptosis, is urgently required. Recently, there is an
increasing interest in the usage of agents derived from
natural products for cancer therapy. Plant products
with strong antioxidant activities are called polyphe-
nols and their effects on cell proliferation, gene regu-
lation and apoptosis have been studied on several
cancer cells.6
Resveratrol (trans-3,4′,5-trihydroxystilbene), a kind
of naturally occurring polyphenolic compound, is pro-
duced in a wide variety of plants like the skin of red
grapes, peanuts, and mulberries to protect them
against pathogenic attacts, injury and UV radiation.7,8
It is very well known that resveratrol shows antioxi-
dant, cardioprotective, chemopreventive, anticarcino-
genic, antiproliferative and anti-inflammatory effects
both in vivo and in vitro.9,10 Resveratrol has been
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shown to induce apoptosis in a variety of cancers such
as chronic myeloid leukemia (CML), acute myeloid
leukemia (AML), breast, prostate, colon and lung
cancers.11–13 The exact mechanism of resveratrol
mediated anticancer effect is not fully identified.
As indicated in several studies, resveratrol-induced
apoptotic mechanisms include inhibition of retino-
blastoma (Rb) phosphorylation, suppression of NF-
κB and STAT3, induction of p2111,14 and ceramide
synthases and inhibition of sphingosine kinase-1 and
glucosyle ceramide synthase.12,13 It has been also
shown that resveratrol inhibits the cell cycle pro-
gression by causing arrest at G1/G2 phases.15
Quercetin, an abundant polyphenol of the flavonoid
family, is generated in onions, apples, red grapes, and
other fruits and vegetables.16 The study of quercetin as
a potential anticancerogen has been paid attention due
to its high toxicity on cancer cells compared with its
relatively scarce effects on normal cells. The antican-
cerogenic effects of quercetin on numerous cancer
cells including melanoma cells, colon, breast, endo-
metrial, T-cell acute lymphoblastic leukemia (ALL),
acute promyelocytic leukemia, and chronic myeloid
leukemia (CML) cells has been described.17
Mechanisms of quercetin triggered apoptosis include
activation of caspases, upregulation of Bax and Bak
and downregulation of Bcl-2 and Bcl-xL and inhi-
bition of telomerase enzyme activity.18–20 Morever,
quercetin inhibits PI3 K-Akt/PKB pathway respon-
sible for cell survival and proliferation. In some
cancer cell types, quercetin induces apoptosis by upre-
gulating death receptor-5.21
In this study, we have shown that resveratrol and
quercetin, most abundant polyphenols, have cytotoxic
and apoptotic effects on human 232B4 CLL cells.
These two polyphenols induce apoptosis through loss
of mitochondrial membrane potential and increases
in caspase-3 enzyme activity.
Materials & methods
Chemicals
Resveratrol was obtained from Sigma-Aldrich (MO,
USA). Resveratrol was dissolved in dimethylsulfoxide
(DMSO) at a final concentration of 10 mM, stored at
−20°C. Quercetin was obtained from Prof. Dr. Güray
Saydam from Ege University, Department of
Hematology. 10 mM stock solution of quercetin was
prepared in DMSO and stored at −20°C. The final
concentration of DMSO did not exceed more than
0.1% in culture.
Cell lines and culture conditions
Human 232B4 CLL cells were kindly provided by
Prof. Dr. Ander Rosen from Linköping University.
The cells were grown and maintained in RPMI-1640
medium containing 10% fetal bovine serum and 1%
penicillin–streptomycin at 37°C in 5% CO2.
Measurement of cell growth by MTT cell
proliferation assay
The IC50 values (drug concentration that inhibits cell
proliferation by 50%) of resveratrol and quercetin were
determined from cell proliferation plots obtained by
MTT assay. Briefly, 2 × 104 cells were seeded into
96-well plates containing 100 μL growth medium in
the absence or presence of increasing concentrations
of resveratrol and quercetin. After 24-, 48- and 72
hours incubation periods for resveratrol and 72
hours for quercetin, the cells were treated with 20 μL
of MTT reagent for 4 hours. Then, the plates were
read under 570-nm wavelengths by ELISA reader
(Thermo Electron Corporation Multiskan Spectrum,
Vantaa, Finland). Finally, IC50 values of resveratrol
and quercetin were calculated from the cell prolifer-
ation plots.22
Measurements of caspase-3 enzyme activity
Changes in caspase-3 enzyme activity of the cells
treated with increasing concentrations of resveratrol
and quercetin for 48 hours were examined by
caspase-3 colorimetric assay kit (BioVision Research
Products, CA, USA). In short, the cells (1 × 106
cells/2 mL/well) were collected by centrifugation at
1000 rpm for 10 minutes. 50 μl of chilled cell lysis
buffer was added onto pellets. The obtained cell
lysates were incubated on ice for 10 minutes and cen-
trifuged at 10 000 g for 1 minutes. Supernatants were
transferred to new Eppendorf tubes and the reaction
mixture containing 50 μl of 2X reaction buffer (con-
taining 10 mM DTT), 50 μl of sample and 5 μl of
DEVD-pNA substrate was prepared in 96 well plate
and incubated for 2 hours at 37°C in a CO2 incubator.
Then, the plate was read under 405 nm wavelengths by
ELISA reader (Thermo Electron Corporation
Multiskan Spectrum, Vantaa, Finland). The absor-
bance values are normalized to protein concentrations
determined by Bradford assay.
Evaluation of apoptosis
For detection of apoptosis, Annexin V-FITC apopto-
sis detection kit (BioVision Research Products, CA,
USA) was used with minor modifications and percen-
tage apoptosis was measured by flow cytometry analy-
sis. 232B4 cells (1 × 106/2 mL/well) were exposed to
different concentrations of resveratrol and quercetin
for 48 hours. After treatment, cells were collected,
washed twice with PBS, and resuspended in 500 μL
binding buffer. Later, 5 μL of annexin V-FITC and
5 μL of propidium iodide (PI) were added to the sus-
pension and the cells were then incubated in the dark
for 15 minutes at room temperature. Samples were
then analyzed by flow cytometer. This method is
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based on the detection of phosphatidylserine (PS)
which is translocated from the inner face of the
plasma membrane to the cell surface soon after the
induction of apoptosis. PS can be easily detected by
staining with a fluorescent conjugate of Annexin V.
Cell cycle analysis
The effects of different concentrations of resveratrol
and quercetin on cell cycle profiles of 232B4 cells at
48 hours were detected in the presence of DNase-free
RNase and propidium iodine (PI) by flow cytometry.
For cell cycle analysis, 232B4 cells (1 × 106/2 mL/
well) were collected by centrifugation at 1200 rpm
for 5 minutes and supernatants were removed. Then,
pellets was dissolved with 1 ml of cold PBS. After
resuspension of pellets, 4 ml of cold absolute ethanol
was added to the pellets with gentle vortexing. The
cell suspension was kept at −20°C at least for 1 day.
At the day of staining, the samples were centrifugated
at 1200 rpm for 10 minutes at 4°C. Supernatants were
removed and pellets were resuspended in 5 ml cold
PBS. Samples were centrifugated at 1200 rpm for 10
minutes. Then, pellets were dissolved in 1 ml of
PBS-triton (100X). 100 μl RNAase-A (200 μg/ml)
was added onto the solution and incubated at 37°C
for 30 minutes. Finally, the cells were stained with
100 μl PI (1 mg/ml) and incubated at room
temperature for 10 minutes. Then, cell cycle profiles
of the cells were analyzed by flow cytometry.
Results
Resveratrol and Quercetin decreased proliferation of
human 232B4 CLL cells in a dose dependent-manner.
In order to determine antiproliferative effects of
resveratrol and quercetin on 232B4 CLL cells, MTT
cell proliferation assay was conducted after 72 hours
incubation period of CLL cells with increasing
concentrations of Resveratrol and Quercetin. The
results displayed that resveratrol and quercetin caused
dose-dependent decreases in 232B4 proliferation as
compared to untreated control samples. IC50 valuses
of resveratrol (Fig. 1A) and quercetin (Fig. 1B) were
found to be 27- and 24 μM, respectively.
Resveratrol and Quercetin induce apoptosis in
232B4 cells. Changes in caspase-3 enzyme activity,
loss of MMP and Annexin-V-FITC staining to deter-
mine apoptotic cell populations were examined in
order to demonstrate apoptotic effects of resveratrol
and quercetin on 232B4 CLL cells. As shown in
Fig. 2A, there were 2-, 16-, 38-, 49- and 107% increases
in caspase-3 activity in response to 0,5-, 1-, 10-, 50 and
100 μM resveratrol, respectively. 0,1-, 5, 10 and 50 μM
quercetin increased caspase-3 activity 3-, 12-, 38 and
47%, respectively.
Figure 1 Cytotoxic effects of resveratrol (A) and quercetin
(B) on human 232B4 CLL cells. The IC50 values of resveratrol
and quercetin were calculated from cell proliferation plots.
The results are the means of three independent experiments.
The error bars represent the standart deviations.
Figure 2 Changes in caspase-3 enzyme activiy in response
to resveratrol (A) and quercetin (B). The results are the means
of three independent experiments. The error bars represent
the standart deviations.
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Resveratrol and quercetin induced apoptosis was
further confirmed by Annexin V-FITC/PI double
staining. Annexin V-positive/PI negative cells were
considered early apoptotic, Annexin V-positive and
PI positive cells were late apoptotic. After 48 hours
of treatment of 232B4 cells with stepwise increasing
concentrations of resveratrol (Figs. 3A and 3B) and
quercetin (Figs. 4A and 4B), total apoptotic cell popu-
lation (late apoptotic plus early apoptotic) increased in
a dose-dependent manner. There were 2-, 8-, 133-, 350-
and 382% increases in apoptotic cells in response to
0,5-, 1-, 10-, 50- and 100 μM resveratrol, respectively,
as compared to untreated 232B4 cells (Figs. 3A and
3B). Quercetin increased apoptotic cell population
56-, 133-, 160-, 297- and 331% in response to 0,1-, 1-
, 10-, 50- and 100 μM, respectively (Figs. 4A and 4B).
Resveratrol and Quercetin inhibits cell cycle pro-
gression. Cell cycle analysis using flow cytometry
was carried out to determine if resveratrol and querce-
tin inhibits cell proliferation. The results revealed that
resveratrol application increased percentage of cell
population in G0/G1 phase, which was accompanied
by a corresponding reduction in the percentage of cells
in S phase in a dose dependent manner (Fig. 5).
Treatment with quercetin increased the cell population
at G0/G1 and decreased the percentage of cells in
G2/M phases at the same time as compared to
untreated control (Fig. 6).
Discussion
In present study, we demonstrated that resveratrol and
quercetin inhibits cell proliferation and cell cycle
progression and induces apoptosis in CLL cells. IC50
values of resveratrol and quercetin was 27- and 24 μM,
respectively. Cytotoxic effects of resveratrol on different
types of cells have been reported previously. The IC50 for
resveratrol was 45 μM on lung cancer cells and this
concentration is effective on many tumor cell types.
Resveratrol may possess potential therapeutic activity
against lung cancer cells, without significantly affecting
the viability of normal cells at its therapeutic concen-
trations.23 Resveratrol suppressed the colony-forming
growth of OCI/AML and OCIM2 cell lines in a
dose-dependent fashion at concentrations ranging from
10 to 75 μM. Inmost studies, resveratrolwas used at con-
centrations ranging from 5 to 100 μM.19 It was reported
that quercetin, at a concentration of 20 mM, exhibits
an antiproliferative effect on U937 cells.19 Quercetin
inhibited cell proliferation in a dose-dependent manner
without affecting cell viability. Quercetin-induced
inhibition of cell proliferation has been reported for
various cancer cells.24
Caspase-3, a key factor in apoptosis execution, is the
active form of procaspase-325 whose activation down-
stream in the apoptotic cascade is essential for leuke-
mia cell apoptosis.26 We used an approach similar to
that in a previous study in which we tested the effect
of resveratrol on caspase-3 activity in CLL cells.
Resveratrol activated caspase-3 in CLL cells. We pre-
viously demonstrated activation of caspase-3 enzyme
activity in response to resveratrol in imatinib-sensitive
and -resistant chronic myeloid leukemia and acute pro-
myelocytic leukemia cells.27 Estrov et al. applied
resveratrol and two caspase inhibitors on OCIM2
cells and reported that both caspase inhibitors par-
tially reversed the antiproliferative effect of resveratrol.
To further determine whether resveratrol activates the
caspase pathway, they incubated OCIM2 cells in the
absence or presence of resveratrol. Incubation of
OCIM2 cells with resveratrol reduced the levels of pro-
caspase-3, and increased the levels of the biologically
active caspase-3.28 Our results were in agreement
with the previous studies.
Resveratrol, through different regulatory mechan-
isms, has been shown to induce apoptosis in tumor
cells.29–32 The mechanisms of resveratrol-induced sup-
pression of cellular proliferation have been reported to
involve the induction of apoptosis through Fas/CD95,
mitochondrial and p53 mediated pathways,29–32 upre-
gulation of CHOP gene expression.33 In addition,
resveratrol suppressed NF-kB and protein kinase-C
activity, and modulated the angiogenesis and
expression of various growth factors as well as NO/
NOS.34–38 Our group previously reported that resvera-
trol triggers apoptosis through up-regulating longevity
assurance (LASS) genes that generate apoptotic cera-
mides and by down-regulating sphingosine kinase-1
and glucosylceramide synthase genes that convert
apoptotic ceramides to antiapoptotic sphingosine-1-
phosphate and glucosylceramide lipids, respectively,
in acute myeloid leukemia and CML cells.12,13 Lee
et al. observed that quercetin inhibits cell growth and
induces apoptosis in colon cancer cells, and that
this may be mediated by its ability to down-regulate
ErbB2/ErbB3 signaling and Akt pathway.13
Quercetin-induced apoptosis in SW-872 human lipo-
sarcoma cells was associated with the loss of mito-
chondrial membrane potential. The apoptosis in
SW-872 human liposarcoma cells induced by querce-
tin was mediated through the activation of caspase-3,
Bax, and Bak and then cleavage of PARP and
downregulation of Bcl-2.12 Kim et al. showed that
antiproliferative effect of quercetin is mediated via
inhibition of PI-3 kinase in cancer cells.24
Our results revealed that resveratrol treatment
induced a dose-dependent increase in the percentage
of cells in G0/G1 phase, which was accompanied by
a corresponding reduction in the percentage of cells
in S phase. A number of studies reported that variety
of different human cancer cell lines, treated with
resveratrol at micromolar concentrations, arrested the
cell cycle progression in S phase39 or less frequently
Gokbulut et al. Resveratrol and quercetin-induced apoptosis
Hematology 2013 VOL. 18 NO. 3 147
in the G2/M phase.40 Resveratrol has been shown to
modulate the major cell cycle mediators at micromolar
concentrations, arresting cancer cells at the G1/S
phase of the different cancer cell.25 After exposure to
50 μM resveratrol, 64.6% of the AML cells were
arrested at the S phase, whereas only 10.9% were at
the G2/M phase and 13.6% at the G0/G1 phase of
the cell cycle.33 Parka et al. observed that resveratrol
arrested cell cycle progression in the S through G2/
M phase in human histiocytic lymphoma U-937
cells.39 Della Ragione et al. reported that lower con-
centrations of resveratrol is a differentiation-inducer,
causing arrest in the S-phase without subsequent
apoptosis in HL60 leukemia cells.39 Treatment with
quercetin increased the cell population at G0/G1
and decreased the percentage of cells in G2/M
phases at the same time as compared to control. On
the contary, in previous studies, it was shown that
U-937 cells treated with quercetin remarkably accumu-
lated in the G2/M phase of the cell cycle in a time
dependent manner up to approximately 80% by 24
hours19 and U-937 cells were accumulated mainly at
G2/M phase when incubated with 50 mM quercetin
for 24 hours.41 Kang and Liang showed that quercetin
inhibited the growth of HL-60 leukemia cells in a dose-
dependent manner and increase the cell number in
G2/M phase.42
The results of this study clearly revealed that resver-
atrol and quercetin induce apoptosis in 232B4 human
CLL cells. Furthermore, our results indicated that the
growth-inhibitory property of quercetin and resvera-
trol was mainly due to the induction of apoptosis as
evidenced by collapse of mitochondrial membrane
potential and activation of caspase-3. These results
also suggest that quercetin and resveratrol may be
useful for the treatment of human CLL.
Figure 3 Evaluation of apoptosis in 232B4 cells induced by resveratrol. The percentage of cells undergoing early and late
apoptosis in a dose-dependentmanner as compared to control and FACS analysis via Annexin V-FITC/PI staining (A & B). Cells in
the lower right quadrant indicate Annexin-positive/PI negative, early apoptotic cells. The cells in the upper right quadrant
indicate Annexin-positive/PI positive, late apoptotic.
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